Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

被引：0

作者：

Kumar, S. K. ^{[1
]}

Moreau, P. ^{[2
]}

Bahlis, N. ^{[3
]}

Facon, T. ^{[4
]}

Plesner, T. ^{[5
,6
]}

Orlowski, R. Z. ^{[7
]}

Basu, S. ^{[8
,9
]}

Nahi, H. ^{[10
]}

Hulin, C. ^{[11
]}

Quach, H. ^{[12
]}

Goldschmidt, H. ^{[13
,14
]}

O'Dwyer, M. ^{[15
]}

Perrot, A. ^{[16
]}

Venner, C. P. ^{[17
,18
]}

Weisel, K. ^{[19
]}

Raje, N. ^{[20
]}

Tiab, M. ^{[21
]}

Macro, M. ^{[22
]}

Frenzel, L. ^{[23
]}

Leleu, X. ^{[24
]}

Wang, G. ^{[25
]}

Krevvata, M. ^{[25
]}

Carson, R. ^{[25
]}

Borgsten, F. ^{[26
]}

Usmani, S. Z. ^{[27
]}

机构：

[1] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[2] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[3] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[4] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[8] Royal Wolverhampton NHS Trust, Wolverhampton, England

[9] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, England

[10] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[11] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[12] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[13] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[14] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[15] NUI, Dept Med Haematol, Galway, Ireland

[16] Univ Toulouse, CHU Toulouse, Serv Hematol, IUCT O,UPS, Toulouse, France

[17] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[18] BC Canc, Vancouver Ctr Grp, Vancouver, BC, Canada

[19] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[20] Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, Boston, MA 02114 USA

[21] CHD Vendee, La Roche Sur Yon, France

[22] Ctr Hosp Univ CHU Caen, Caen, France

[23] Hop Necker Enfants Malad, Paris, France

[24] CHU Poitiers, Hop Miletrie, Poitiers, France

[25] Janssen Res & Dev LLC, Spring House, PA USA

[26] Janssen Res & Dev LLC, Raritan, NJ USA

[27] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P342

引用

页码：183 / 184

页数：2

共 50 条

[41] UPDATED EFFICACY AND SAFETY ANALYSIS OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRd) VERSUS LENALIDOMIDE AND DEXAMETHASONE (Rd) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM; POLLUX)
Moreau, P.
White, D.
Benboubker, L.
Cook, G.
Leiba, M.
Morton, J.
Ho, P. J.
Kim, K.
Takezako, N.
Trivedi, S.
Wu, K.
Casneuf, T.
Chiu, C.
Schecter, J. M.
Dimopoulos, M. A.
HAEMATOLOGICA, 2018, 103 : 31 - 31
[42] Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux
Dimopoulos, Meletios A.
White, Darrell J.
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Trivedi, Sonali
Wu, Kaida
Casneuf, Tineke
Chiu, Christopher
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[43] Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
Orlowski, Robert Z.
Goldschmidt, Hartmut
Cavo, Michele
Martin, Thomas G.
Paux, Gautier
Oprea, Corina
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[44] Sustained Improvement in HealthRelated Quality of Life in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Perrot, Aurore
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Magaret
Frenzel, Laurent
Leleu, Xavier
Liu, Kevin
Fastenau, John
Gries, Katharine S.
Ho, Kai Fai
Mistry, Pankaj
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad Z.
BLOOD, 2021, 138
[45] Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).
Ocio, Enrique M.
Rodriguez Otero, Paula
Bringhen, Sara
Oliva, Stefania
Nogai, Axel
Attal, Michel
Moreau, Philippe
Martinez-Lopez, Joaquin
Le Roux, Nadia
Mace, Sandrine
Rouchon, Marie-Claude
Wang, Qiuyan
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[46] A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
O'Donnell, Elizabeth K.
Laubach, Jacob P.
Yee, Andrew J.
Chen, Tianqi
Huff, Carol Ann
Basile, Frank G.
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Burke, Jill N.
Harrington, Cynthia C.
Lively, Kathleen J.
Lyons, Hannah F.
Munshi, Nikhil C.
Anderson, Kenneth C.
Trippa, Lorenzo
Richardson, Paul G.
Raje, Noopur S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 222 - 230
[47] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
Nooka, Ajay
Kaufman, Jonathan
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah
Anderson, Larry
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas
Usmani, Saad
Richardson, Paul
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
[48] Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
Wang, Yan
Liu, Yuan-Fang
Jin, Shi-Wei
Tao, Yi
Zhang, Wei-Ping
Chen, Jian-Lin
Jiang, Song-Fu
Mi, Jian-Qing
SCIENTIFIC REPORTS, 2025, 15 (01):
[49] A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM)
Khan, M. L.
Reeder, C. B.
Kumar, S.
Lacy, M.
Reece, D. E.
Laumann, K. M.
Mikhael, J.
Fonseca, R.
Rajkumar, V.
Stewart, A. K.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[50] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth K.
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol A.
Basile, Frank G.
Wade, Philip M., Jr.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole R.
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul C.
Raje, Noopur S.
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →